Plasma Metabonomics of Human Adenovirus-infected Patients with Pneumonia and Upper Respiratory Tract Infection
© 2024. Huazhong University of Science and Technology..
OBJECTIVE: Human adenovirus (HAdV) infection is common and can develop to serious conditions with high mortality, yet the mechanism of HAdV infection remains unclear. In the present study, the serum metabolite profiles of HAdV-7-infected patients with pneumonia or upper respiratory tract infection (URTI) were explored.
METHODS: In total, 35 patients were enrolled in the study following an outbreak of HAdV-7 in the army, of whom 14 had pneumonia and 21 had URTI. Blood samples were collected at the acute stage and at the recovery stage and were analyzed by untargeted metabolomics.
RESULTS: Over 90% of the differential metabolites identified between the pneumonia patients and URTI patients were lipids and lipid-like molecules, including glycerophospholipids, fatty acyls, and sphingolipids. The metabolic pathways that were significantly enriched were primarily the lipid metabolism pathways, including sphingolipid metabolism, glycerophospholipid metabolism, and linoleic acid metabolism. The sphingolipid metabolism was identified as a significantly differential pathway between the pneumonia patients and URTI patients and between the acute and recovery stages for the pneumonia patients, but not between the acute and recovery stages for the URTI patients. Ceramide and lactosylceramide, involved in sphingolipid metabolism, were significantly higher in the pneumonia patients than in the URTI patients with good discrimination abilities [area under curve (AUC) 0.742 and 0.716, respectively; combination AUC 0.801].
CONCLUSION: Our results suggested that HAdV modulated lipid metabolism for both the patients with URTI and pneumonia, especially the sphingolipid metabolism involving ceramide and lactosylceramide, which might thus be a potential intervention target in the treatment of HAdV infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Current medical science - 44(2024), 1 vom: 23. Feb., Seite 121-133 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wei, Ting-Ting [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4682-48-8 |
|---|
| Anmerkungen: |
Date Completed 26.02.2024 Date Revised 26.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11596-024-2835-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368835103 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368835103 | ||
| 003 | DE-627 | ||
| 005 | 20240229155549.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11596-024-2835-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1306.xml |
| 035 | |a (DE-627)NLM368835103 | ||
| 035 | |a (NLM)38393525 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wei, Ting-Ting |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Plasma Metabonomics of Human Adenovirus-infected Patients with Pneumonia and Upper Respiratory Tract Infection |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2024 | ||
| 500 | |a Date Revised 26.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. Huazhong University of Science and Technology. | ||
| 520 | |a OBJECTIVE: Human adenovirus (HAdV) infection is common and can develop to serious conditions with high mortality, yet the mechanism of HAdV infection remains unclear. In the present study, the serum metabolite profiles of HAdV-7-infected patients with pneumonia or upper respiratory tract infection (URTI) were explored | ||
| 520 | |a METHODS: In total, 35 patients were enrolled in the study following an outbreak of HAdV-7 in the army, of whom 14 had pneumonia and 21 had URTI. Blood samples were collected at the acute stage and at the recovery stage and were analyzed by untargeted metabolomics | ||
| 520 | |a RESULTS: Over 90% of the differential metabolites identified between the pneumonia patients and URTI patients were lipids and lipid-like molecules, including glycerophospholipids, fatty acyls, and sphingolipids. The metabolic pathways that were significantly enriched were primarily the lipid metabolism pathways, including sphingolipid metabolism, glycerophospholipid metabolism, and linoleic acid metabolism. The sphingolipid metabolism was identified as a significantly differential pathway between the pneumonia patients and URTI patients and between the acute and recovery stages for the pneumonia patients, but not between the acute and recovery stages for the URTI patients. Ceramide and lactosylceramide, involved in sphingolipid metabolism, were significantly higher in the pneumonia patients than in the URTI patients with good discrimination abilities [area under curve (AUC) 0.742 and 0.716, respectively; combination AUC 0.801] | ||
| 520 | |a CONCLUSION: Our results suggested that HAdV modulated lipid metabolism for both the patients with URTI and pneumonia, especially the sphingolipid metabolism involving ceramide and lactosylceramide, which might thus be a potential intervention target in the treatment of HAdV infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a human adenovirus | |
| 650 | 4 | |a lipids | |
| 650 | 4 | |a metabonomic | |
| 650 | 4 | |a pneumonia | |
| 650 | 4 | |a upper respiratory tract infection | |
| 650 | 7 | |a CDw17 antigen |2 NLM | |
| 650 | 7 | |a 4682-48-8 |2 NLM | |
| 650 | 7 | |a Lactosylceramides |2 NLM | |
| 650 | 7 | |a Antigens, CD |2 NLM | |
| 700 | 1 | |a Xu, Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Tu, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wan-Xue |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Xin-Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Yiguo |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Shan-Shan |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jun-Lian |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Ming-Zhu |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Wei-Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Qing-Bin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current medical science |d 2018 |g 44(2024), 1 vom: 23. Feb., Seite 121-133 |w (DE-627)NLM287137252 |x 2523-899X |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2024 |g number:1 |g day:23 |g month:02 |g pages:121-133 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11596-024-2835-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2024 |e 1 |b 23 |c 02 |h 121-133 | ||